Form 4: Xenon Pharmaceuticals Director Acquires Stock Options

Elizabeth A. Garofalo, a director of Xenon Pharmaceuticals Inc., acquired stock options exercisable for 15,542 common shares on June 5, 2024.

Summary

• On June 5, 2024, Elizabeth A. Garofalo, a director of Xenon Pharmaceuticals Inc. (XENE), acquired stock options.
• The stock options grant the right to buy 15,542 common shares at an exercise price of $38.16.
• The options vest 100% on the earlier of June 4, 2025, or the day before the issuer's 2025 annual meeting of shareholders.
• The options expire on June 4, 2034.
• Following the transaction, Garofalo directly owns 15,542 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider transactions.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders if it signals confidence from a company director.

Key Dates